Medifast FY 2024: revenue $602.5M, down 44%; diluted EPS $0.19

Key figures from this report

These are the numbers Medifast reported for the year ended Dec 31, 2024, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

1. Revenue$602.5M−44% from $1.1B in FY 202310-K income statement, on EDGAR
2. Net income$2.1M−98% from $99.4M in FY 202310-K income statement, on EDGAR
3. Diluted EPS$0.19−98% from $9.10 in FY 202310-K income statement, on EDGAR
4. Cash and cash equivalents$90.9M−4% from $94.4M in FY 2023Cash and equivalents only; the company page adds short-term investments.10-K balance sheet, on EDGAR
5. Cash from operations$24.5M−83% from $147.7M in FY 202310-K cash flow statement, on EDGAR

Every year in the financial tables